- Rated 5.00 out of 5199,99 €
This article directly stems from the research process for our global venture capital investors database. Based on this list and our advanced keyword crawler technology, we created a list of venture capital investors that mention biotech investment keywords on their website. The list – offered as an Excel file – is perfectly suited to get in touch with the most relevant investors in the field.
The United Kingdom has emerged as a major part of the high-growth life science sector, especially during the COVID-19 pandemic due to the Astrazeneca vaccine. This article highlights three of the biggest biotech venture capital investors in the UK from our keyword-crawler based life science investor list.
1. o2h Ventures (Cambridge)
The o2h ventures company are pioneers in the biotech sector. They are actively involved investors and aim to expand early-stage research and development in the United Kingdom. The company’s business model looked to Wuxi Ventures for their approach and access to opportunities and to Atlas Ventures for the post-investment requirements and incubation. Two promising companies in their portfolio are Xploro, who use artificial intelligence and other computer-based programmes to reduce stress and anxiety and Neurocentrx Pharma Ltd, who develop medicine for neurological conditions.
2. Neo Kuma Ventures (London)
Neo Kuma aims to advance and improve standard patient care by investing in early seed psychedelic health-care businesses. The company’s strategy constitutes of enabling the use of psychedelic therapies to treat the cause of mental illnesses. They invest in compounds, digital platforms, and clinics and care delivery and offer a close-knit relationship with the leaders in the life science sector. Current portfolio companies include Beckley Psytech, a company developing psychedelic pharmacotherapy and psychotherapy, and Awakn, a biotech company researching treatments for addiction.
3. Selvedge Venture (London)
Selvedge Venture strive to improve the health-care system by investing in early-stage companies that target the treatment of age-related conditions such as metabolic syndrome, cancer, and neurodegenerative diseases. They use state of the art technology regarding biotechnology, machine learning tools and Integrated data assets. Three examples of interesting portfolio companies are, Exogene, who develop T-cell-receptor-based cell therapies to target cancer and cell aging, then Sanome, a biomarker platform, and, finally, Avro life science, who invented skin patches to administer slow-release medication.
Picture Source: Louis Reed